-+ 0.00%
-+ 0.00%
-+ 0.00%

Simcere says China approves RSV prevention antibody Yingmule for infants

PUBT·09/03/2026 13:27:35
Listen to the news
Simcere says China approves RSV prevention antibody Yingmule for infants
  • China’s NMPA cleared Yingmule (culevibart injection) for marketing on Sept. 3, 2026.
  • Product targets RSV prevention in newborns and infants born at or after 35 weeks’ gestation entering their first RSV season.
  • Simcere holds exclusive Greater China commercialization rights under a strategic cooperation with Reyoung Bio signed Aug. 20, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12319544), on September 03, 2026, and is solely responsible for the information contained therein.